Samsara BioCapital, LLC - Q1 2020 holdings

$174 Million is the total value of Samsara BioCapital, LLC's 28 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 47.4% .

 Value Shares↓ Weighting
ICPT  Intercept Pharmaceuticals Inc$25,416,000
-49.2%
403,6880.0%14.63%
-39.0%
PRNB BuyPrincipia Biopharma Inc$23,814,000
+41.7%
401,046
+30.7%
13.70%
+70.2%
SWTX SellSpringworks Therapeutics Inc$16,883,000
-32.9%
625,281
-4.3%
9.72%
-19.4%
ODT  Odonate Therapeutics Inc$14,430,000
-14.9%
522,6370.0%8.30%
+2.2%
ALLK BuyAllakos Inc$12,055,000
-47.9%
270,965
+11.7%
6.94%
-37.4%
STRO  Sutro BioPharma Inc$11,481,000
-7.3%
1,125,5790.0%6.61%
+11.4%
BCEL BuyAtreca Inc$9,878,000
+8.0%
596,838
+0.9%
5.68%
+29.7%
SYRS  Syros Pharmaceuticals Inc$9,599,000
-14.7%
1,726,6030.0%5.52%
+2.4%
LQDA BuyLiquidia Technologies Inc$4,775,000
+16.5%
1,013,773
+5.8%
2.75%
+40.0%
HOOK  Hookipa Pharma Inc$4,375,000
-32.5%
530,2450.0%2.52%
-19.0%
RYTM NewRhythm Pharmaceuticals Inc$4,205,000276,289
+100.0%
2.42%
MLND BuyMillendo Therapeutics Inc$3,967,000
-17.7%
751,301
+5.0%
2.28%
-1.1%
BLU SellBellus Health Inc$3,917,000
+6.1%
394,431
-19.3%
2.25%
+27.4%
PIRS BuyPieris Pharmaceuticals Inc$3,694,000
+44.9%
1,620,249
+130.1%
2.13%
+74.1%
AIMT NewAimmune Therapeutics, Inc.$3,354,000232,571
+100.0%
1.93%
ARAV  Aravive Inc$3,318,000
-57.9%
576,0660.0%1.91%
-49.4%
ISEE BuyIveric Bio, Inc.$2,967,000
-50.6%
862,552
+23.2%
1.71%
-40.7%
ACRS NewAclaris Therapeutics, Inc.$2,712,0002,608,117
+100.0%
1.56%
SNSS  Sunesis Pharmaceuticals Inc$2,464,000
+22.9%
5,938,2150.0%1.42%
+47.6%
RCKT NewRocket Pharmaceuticals Inc$1,788,000128,197
+100.0%
1.03%
UROV  Urovant Sciences Ltd$1,452,000
-40.6%
157,4800.0%0.84%
-28.6%
KALV BuyKalVista Pharmaceuticals Inc$1,287,000
-39.0%
168,174
+41.9%
0.74%
-26.7%
 Catabasis Pharmaceuticals Inc$1,245,000
-29.8%
300,0000.0%0.72%
-15.6%
PTLA NewPortola Pharmaceuticals Inc$1,139,000159,772
+100.0%
0.66%
BLUE NewBluebird Bio Inc$1,139,00024,790
+100.0%
0.66%
AKRO NewAkero Therapeutics, Inc.$1,060,00050,000
+100.0%
0.61%
AMRN NewAmarin Corp PLCspons adr new$781,000195,195
+100.0%
0.45%
KALA NewKala Pharmaceuticals Inc$563,00064,102
+100.0%
0.32%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Intercept Pharmaceuticals Inc20Q3 202324.0%
ALLAKOS INC20Q3 202323.0%
SUTRO BIOPHARMA INC20Q3 202310.1%
SYROS PHARMACEUTICALS INC16Q3 202211.6%
ATRECA INC16Q1 20237.4%
IVERIC BIO INC15Q2 20235.5%
ACLARIS THERAPEUTICS INC15Q3 20234.8%
RHYTHM PHARMACEUTICALS INC15Q3 20232.4%
ODONATE THERAPEUTICS INC14Q1 202214.9%
SPRINGWORKS THERAPEUTICS INC14Q4 202212.1%

View Samsara BioCapital, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR/A2023-08-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR/A2023-02-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16

View Samsara BioCapital, LLC's complete filings history.

Compare quarters

Export Samsara BioCapital, LLC's holdings